Skip to main content
Equibles
KYMR logo

KYMR · Kymera Therapeutics, Inc. · Metrics

Track KYMR — free

Use KYMR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KYMR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$127.17 -7.67 (-5.69%) At close · Nov 12 Play latest call Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$10.86B
Shares
85.37M
Volume · Nov 12 685.11K Avg daily vol (3M) 823.63K

KYMR metrics

90 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$127.17
Market cap
$10.86B

Price action

23 metrics
Price change (1W)
-1.0%
Price change (30D)
+26.4%
Price change (3M)
+18.2%
Price change (6M)
+57.5%
Price change (YTD)
+73.3%
Price change (1Y)
+112.8%
Trailing year
Price change (5Y)
+113.4%
52-week high
$138.86
52-week low
$63.37
Change from 52-week high
-2.9%
Change from 52-week low
+112.8%
Annualized volatility
62.8%
Annualized volatility (3M)
43.7%
Implied volatility (30D)
115.9%
IV rank (1Y)
51.0
IV percentile (1Y)
86.1
Beta
0.9
RSI (14D)
64.5
Price vs SMA 50
+15.5%
Price vs SMA 200
+36.3%
Avg volume (3M)
827,871
Relative volume
0.7
Average dollar volume
$98.12M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
85.37M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
103.1×
reciprocal yield 1.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
112.6×
reciprocal yield 0.9%
P / book
7.1
reciprocal yield 14.0%
FCF yield
-2.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
58.3×
reciprocal yield 1.7%
EV / revenue historical average (5Y)
45.3×
reciprocal yield 2.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-29

Profitability

9 metrics
Gross margin
0.0%
Operating margin
-396.0%
Trailing 12 months
Net margin
-341.8%
Gross profit (TTM)
$0
Operating profit (TTM)
−$404.89M
Net income (TTM)
−$349.43M
Trailing 12 months
Diluted EPS (TTM)
$-3.63
FCF margin
-282.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.05
Gross profit per diluted share (TTM)
$0.00
Operating profit per diluted share (TTM)
$-4.19
EBITDA per diluted share (TTM)
$-4.11
Net income per diluted share (TTM)
$-3.62
Operating cash flow per diluted share (TTM)
$-2.98
Free cash flow per diluted share (TTM)
$-3.00
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$4.44
Stock compensation per diluted share (TTM)
$0.71
Book value per share
$19.42

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$102.24M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.7%
Year over year · more shares
Revenue CAGR (3Y)
-5.7%
Revenue CAGR (5Y)
+2.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-21.6%
Return on assets
-19.8%
Debt / equity
0.0
Current ratio
11.1
EBITDA (TTM)
−$396.78M
Free cash flow (TTM)
−$288.89M
Quick ratio
11.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$371.40M
Latest balance sheet
Cash & equivalents
$373.37M
Total assets
$1.77B
Total debt
$1.97M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$287.56M
Capital expenditures (TTM)
$1.33M
R&D (TTM)
$429.98M
SG&A (TTM)
—
Stock compensation (TTM)
$68.23M
R&D / revenue
420.6%
Stock compensation / revenue
66.7%

Ownership (13F)

9 metrics
13F filers
278
13F filer change QoQ
+20
Institutional ownership
114.5%
Conviction holders (share of 13F filers)
4.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-1.6%
Holder tenure
16.5
Price vs estimated holder cost
+127.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.1%

Short interest

3 metrics
Short interest
9.8%
Latest settlement · 10.5 days to cover
Days to cover
10.5d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$4.16M
Insider-sentiment score
40 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1815442 CUSIP 501575104 13F (30d) 193 filings 172 filers Visit website Investor relations